RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/14676304http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/14676304http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/14676304http://www.w3.org/2000/01/rdf-schema#comment"Cylindromas are benign adnexal skin tumors caused by germline mutations in the CYLD gene. In most cases the second wild-type allele is lost in tumor tissue, suggesting that CYLD functions as tumor suppressor. CYLD is a protein of 956 amino acids harboring a functional deubiquitinating domain at the COOH-terminal end. To shed more light on the function of CYLD, we have performed a yeast two hybrid screen using an HaCaT cDNA library that identified the RING finger protein TRIP (TRAF-interacting protein) as interactor with full-length CYLD. Mapping of the interacting domains revealed that the central domain of CYLD binds to the COOH-terminal end of TRIP. Far Western analysis and coimmunoprecipitations in mammalian cells confirmed that full-length CYLD binds to the COOH-terminal domain of TRIP. Because TRIP is an inhibitor of nuclear factor (NF)-kappaB activation by tumor necrosis factor (TNF), the effect of CYLD on NF-kappaB activation was investigated in HeLa cells. The results established that CYLD down-regulates NF-kappaB activation by TNF-alpha. The inhibition by CYLD depends on the presence of the central domain interacting with TRIP and its deubiquitinating activity. These findings indicate that cylindromas arise through constitutive NF-kappaB activation leading to hyperproliferation and tumor growth."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.org/dc/terms/identifier"doi:10.1084/jem.20031187"xsd:string
http://purl.uniprot.org/citations/14676304http://purl.org/dc/terms/identifier"doi:10.1084/jem.20031187"xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Huber M."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Huber M."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Hohl D."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Hohl D."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Regamey A."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Regamey A."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Liu J.W."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Liu J.W."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Roger T."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Roger T."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Kogerman P."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Kogerman P."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Toftgaard R."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/author"Toftgaard R."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/date"2003"xsd:gYear
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/date"2003"xsd:gYear
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/name"J. Exp. Med."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/name"J. Exp. Med."xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/pages"1959-1964"xsd:string
http://purl.uniprot.org/citations/14676304http://purl.uniprot.org/core/pages"1959-1964"xsd:string